CYLD is a tumour suppressor gene mutated in familial cylindromatosis, a genetic disorder leading to the development of skin appendage tumours. It encodes a deubiquitinating enzyme that removes Lys63-or linear-linked ubiquitin chains. CYLD was shown to regulate cell proliferation, cell survival and inflammatory responses, through various signalling pathways. Here we show that CYLD localizes at centrosomes and basal bodies via interaction with the centrosomal protein CAP350 and demonstrate that CYLD must be both at the centrosome and catalytically active to promote ciliogenesis independently of NF-kB. In transgenic mice engineered to mimic the smallest truncation found in cylindromatosis patients, CYLD interaction with CAP350 is lost disrupting CYLD centrosome localization, which results in cilia formation defects due to impairment of basal body migration and docking. These results point to an undiscovered regulation of ciliogenesis by Lys63 ubiquitination and provide new perspectives regarding CYLD function that should be considered in the context of cylindromatosis.
C entrioles are conserved microtubule-based organelles displaying structural asymmetry, with the mother centriole bearing two sets of appendages at its distal end. In resting cells, the mother centriole can turn into a so-called basal body and dock to the plasma membrane through the distal appendages, to complete primary cilia formation 1 . In addition to these primary cilia, multiple motile cilia are present in some mammalian epithelia (for example, brain ventricles, respiratory tract and fallopian tubes). In contrast to cycling cells, these multiciliated cells have the ability to assemble hundreds of centrioles that anchor to the plasma membrane and grow cilia 2 . In all cases, ciliogenesis is a multistep process that includes basal body assembly, maturation and migration, transition zone formation, docking to the cell surface and further axonemal extension, which requires intraflagellar transport 3 .
Primary cilia are considered as cell antennas that receive extracellular signals and transmit them to the cell bodies, thus coordinating cell growth, polarity and differentiation 4, 5 . Among their role in sensing the environment, cilia are required to mediate several signal transduction pathways 6 . Therefore, any defects in this organelle lead to a wide range of developmental disorders and diseases grouped under the term 'ciliopathies' 1 .
Among the numerous centrosomal proteins, CAP350 serves as a platform to anchor several proteins to the centrosome. FOP (FGFR1 oncogene partner) localization at the centrosome depends on its association with CAP350 and is required to recruit EB1 at the centrosome 7 . The complex CAP350/FOP was shown to be required for microtubule anchoring to the centrosome. In addition, as a microtubule binding protein CAP350 stabilizes the microtubule network 8 as well as the microtubules of the centriolar barrel 9 , allowing the maintenance of a continuous pericentrosomal golgi ribbon 8 . Interestingly, removal of EB1 from the centrosome by expression of a carboxyterminal fragment of CAP350 as well as depletion of FOP inhibits primary cilia formation 10 .
CYLD was originally identified as a gene mutated in familial cylindromatosis, a genetic condition that predisposes patients to the development of skin appendages tumours, referred to as cylindromas. Patients with cylindromatosis carry heterozygous germ-line mutations in the CYLD gene 11 . During their life, some cells undergo a loss of heterozygosity with the disappearance of the wild-type (WT) CYLD allele. The remaining mutated allele leads to the expression of a truncated protein, thus resulting in the development of cylindromas. Therefore, this mode of tumour formation defines CYLD as a tumour suppressor. The CYLD gene encodes a deubiquitinating (DUB) enzyme, which removes lysine 63-linked polyubiquitin chains (K63-linked ubiquitin) as well as linear chains from target proteins 12 . Interestingly, most of the mutations of CYLD found in human cylindromas are predicted to cause C-terminal truncations and catalytic inactivation of the DUB domain.
The CYLD protein was shown to regulate cell survival and inflammatory responses mainly through inhibiting nuclear factor-kB (NF-kB) and mitogen-activated protein (MAP) kinase signalling 13, 14 . In addition, CYLD was also shown to negatively regulate the Wnt/b-catenin signalling pathway by removing K63-linked ubiquitin of Dishevelled (Dvl) 15 , and more recently CYLD was found to interact with the centrosomal protein CEP192 (ref. 16 ), which plays a critical role in centrosome biogenesis 17 .
The tumour suppressing function of CYLD has been studied, in vivo, using Cyld knockout (KO) mice. Surprisingly, these mice do not spontaneously develop tumours but their skin is more sensitive to tumorigenic chemicals compared with WT mice 18 . Intriguingly, transgenic mice, which carry a complete deletion of the DUB domain (Cyld D9/D9 ) die perinatally from respiratory dysfunction and exhibit immature lungs characterized by hyperplasic mesenchyme 19 . The striking difference between those two phenotypes led us to use a knockin mouse model engineered to recapitulate more closely the smallest truncation found in patients by expressing a truncated CYLD protein lacking the last 24 C-terminal amino acids of its catalytic domain (Cyld D932 ).
To further characterize how CYLD may contribute to cylindromatosis onset, we highlight the interaction between CYLD and the centrosomal CAP350 protein, which leads to CYLD localization to the centrosome. In addition, we demonstrate that Cyld D932 mice show impaired apical migration and docking of basal bodies in multiciliated cells with a concomitant loss of CYLD centrosomal localization and CAP350 interaction. To understand the mechanism by which CYLD impairs basal body migration/docking, we expressed several constructs of the protein and show that CYLD overexpression in the cytosol prevents primary cilia formation, while its specific expression at the centrosome leads to primary cilia formation. Conversely, expression of the catalytically inactive CYLD at the centrosome abolishes ciliogenesis. This demonstrates that both centrosome localization and CYLD DUB activity are required for cilia formation. Finally, we demonstrate by inhibiting the NF-kB pathway that catalytically inactive CYLD abolishes ciliogenesis in an NF-kB-independent manner. Altogether, these results point to an unravelled role of Lysine 63 ubiquitination in ciliogenesis.
Results

CYLD interacts with CAP350 at the centrosome/basal bodies.
We identified CYLD as a potential interacting partner of CAP350, by performing immunoprecipitation directed against CAP350 followed by mass spectrometry analysis. Eleven peptides were found in the 110-kDa band that matched sequences throughout the tumour suppressor protein CYLD (Fig. 1a and Supplementary  Fig. 1 ). We confirmed the presence of CYLD in the CAP350 immunoprecipitate using a monoclonal antibody directed against the catalytic domain of CYLD (Fig. 1b) , thus establishing CAP350/CYLD interaction. To further map the interacting domains of CAP350 and CYLD, we transfected Myc-tagged DNA constructs encoding various portions of CAP350 with full-length Flag-tagged CYLD into HEK 293T cells and performed immunoprecipitation with an anti-Flag antibody. The CYLD interacting domain was mapped to the C-terminal domain of CAP350 (Fig. 1c) . As full-length CAP350 is insoluble, we overexpressed the CAP350 C-terminal domain with either a CYLD DN (AA394-956) or CYLD DC (AA1-585) construct. We found that the CAP350 C-terminal domain interacts with a CYLD DN (AA394-956) protein but not with the CYLD DC (AA1-585) protein, suggesting that it interacts with the DUB domain of CYLD (Fig. 1d) . In addition, cells co-expressing both proteins show a colocalization of CAP350-GFP and CYLD-Flag to the centrosome and to the microtubules ( Supplementary Fig. 2a ). Such localization has already been observed for CAP350 overexpression alone, as previously described 8 , while CYLD-Flag expressed alone was present in the cytosolic fraction ( Supplementary Fig. 2b ). These results suggest that CAP350 directs CYLD localization to perform specific functions in cells.
CYLD localizes to the centrosome and basal bodies. This CAP350/CYLD interaction prompted us to investigate the localization of endogenous CYLD. To that end, we generated and affinity purified an antibody directed against CYLD (CYLD 089). Staining with this antibody showed that CYLD is enriched at the centrosome throughout the cell cycle (Fig. 2a,b) . In addition, a faint labelling of the nucleus was observed in interphase cells. Such a nuclear staining has previously been observed for several ciliary or centrosomal proteins 20 . During metaphase, CYLD was detected along some spindle microtubules and at the spindle poles (Fig. 2b) , reminiscent of CAP350 staining 8 . To further ascertain this centrosomal localization, we used a biochemical approach. Western blot (WB) analysis with two antibodies against CYLD identified a major band at 110 kDa, which was specifically enriched in the centrosomal fraction of KE37 cells but also weakly detected in Triton X-100-soluble and -insoluble fractions (Fig. 2c) . Consistent with these observations, purified centrosomes were strongly labelled by CYLD antibodies (Fig. 2d) . We conclude that CYLD is a centrosomal protein.
To confirm the centrosomal localization of CYLD, we investigated its localization in multiciliated cells that contain numerous basal bodies. Serum starvation of cultured ependymal cells leads to the development of numerous motile cilia growing from these basal bodies 21 . Therefore, we cultured ependymal cells from mouse brains and stained them with antibodies against CAP350 and CYLD. Antibodies directed against glycylated tubulin, such as TAP952 (ref. 22) were used to decorate the cilia. Numerous dots located at the cilia base were labelled by antibodies directed against CAP350 or CYLD (Fig. 2e,f) . A co-staining with antibodies directed against g-tubulin suggests that both proteins localize at the basal bodies of multiciliated cells ( Supplementary Fig. 3) . Surprisingly, CYLD antibodies, but not CAP350 antibody, stained the tips of the cilia and weakly the cilia themselves (Fig. 2f) . Altogether, these results suggest that CYLD localizes at the centrosome and basal bodies but also at the ciliary tips.
Truncated CYLD inhibits primary cilia formation. The presence of CYLD at the basal bodies and at the ciliary tips prompted us to investigate the role of this protein in ciliogenesis. Therefore, we turned to Cyld D932 mice 23 , which express the smallest truncation of CYLD causing the human pathology (a deletion of the last 24 amino acids) leading to a catalytically inactive protein 24 (Fig. 1a) . As previously described in mice with complete deletion of CYLD catalytic domain (Cyld D9/D9 ) 19 , Cyld D932 mutants die perinatally from respiratory distress with pulmonary defects ( Supplementary Fig. 4 ) reminiscent of the phenotype observed in several mouse models exhibiting defects in signalling as Wnt5a 25 Fig. 5a -c). As CYLD is a tumour suppressor, and primary cilia usually form in the G0/G1 phase of the cell cycle 28 , we also wanted to determine whether both cell types were able to undergo cell cycle arrest on serum starvation. Again, after FACS analysis and KI67 staining we found no difference in the ratio of non-cycling cells between the two conditions ( Supplementary Fig. 5a-c) . Although both cell types proliferate similarly and are able to stop cycling on serum starvation, primary cilium staining showed that only 32% of Cyld D932 cells present a primary cilium compared with 68% of WT MEFs (Fig. 3a,b) , suggesting that truncated CYLD mildly affects primary cilia formation.
Truncated CYLD inhibits multiple motile cilia formation.W e next examined motile cilia formation in trachea of WT and Cyld D932 E18.5 embryos from several litters by scanning electron microscopy. As ciliogenesis in the trachea occurs proximo-distally 29 , we imaged and counted the ciliated cells in every field from the larynx to the beginning of the main bronchi to avoid bias due to spatial differences. For each litter, the number of multiciliated cells was at least 50% lower in the mutants than in WT embryos. In addition, the motile cilia of mutant multiciliated cells were generally shorter and scarce (Fig. 4a) . As a control of the specificity of this result, we took advantage of the previously published Cyld knock-out mouse model 18, 30, 31 .A sCyld KO mice live without any major health issues, we were not expecting any defects in cilia formation. Indeed, there was no difference in the morphology and number of multiciliated cells between the WT and Cyld KO embryos (Fig. 4a, graph) . These results show that CYLD D932 , a truncated catalytically inactive protein, behaves as a dominant negative form of CYLD to inhibit formation of motile cilia in multiciliated cells, whereas complete absence of CYLD has no effect on cilia formation.
As the decreased number of multiciliated trachea cells might be due to a developmental delay in the Cyld D932 embryo, we used the ependymal culture system 21 and compared motile cilia formation in parallel cell cultures obtained from WT and Cyld D932 littermates. There was no difference in the doubling time of cells with these different genotypes, but there was a dramatic difference in the number of multiciliated cells between WT and Cyld D932 cells, independently of cell-density variations (Fig. 4b) . Altogether, our results in trachea and ependymal cells culture Cyld D932 basal bodies duplicate normally but fail to anchor.To determine the reason of the decrease in cilia formation in Cyld D932 embryos, we studied basal body formation in ependymal cell cultures from each genotype at several differentiation time points by staining with antibodies specific for basal bodies and cilia. In WT cell cultures, multiciliated cells showed abundant basal bodies decorated with anti-centrin3 antibodies (Fig. 5a ). Abundant basal bodies were also observed in Cyld D932 cells irrespective of the number of cilia in these cells. Quantification of cells with numerous basal bodies revealed only a slight decrease in Cyld D932 mutant cells, suggesting that basal bodies amplification proceeds similarly in WT and Cyld D932 cells (Fig. 5a ). In addition, the timing of formation was not different between the two cell types. To further investigate a possible basal body defect, we performed detailed electron microscopy analysis of WT and mutant tracheas. We found that a significant number of basal bodies failed to position apically and dock at the plasma membrane in Cyld D932 tracheal ciliated cells (Fig. 5b) . They appeared to be positioned in different orientation (Fig. 5b, arrows) . In addition, the microvilli, which interspaced the axonema, appeared to be reduced in length as well as in number, compared with the WT samples from the same litter, reminiscent of actin organization or Rho GTPase activity defect 32, 33 . Thus, in mutant cells basal bodies multiply normally but fail to migrate apically, suggesting a defect in transport and/or docking at the apical membrane.
Centriole maturation and satellites are not affected. The failure of basal bodies to anchor could be explained by either a defect in centriole maturation or in centriolar satellite organization. Indeed, centriolar maturation is characterized by the acquisition of subdistal and distal appendages, which form the ciliary basal feet and transition fibres, respectively 34 . Both of them are required for cilia formation. Furthermore, centriolar satellites are believed to drive cargo to the centrosome and basal bodies 35 , and are also required for ciliogenesis 36 . To ascertain the presence of centriolar satellites and appendages, we stained ependymal cells with antibodies directed against PCM1 and OFD1, two proteins of centriolar satellites 35, 36 , as well as with antibodies against Cep164 and CCDC123 (Cep123), two proteins located within the distal appendages 37, 38 , and ODF2, a protein located both at distal and subdistal appendages 39 . All antibodies decorated centriolar satellites or basal bodies irrespective of the genotype (Fig. 6 ), suggesting that basal body maturation and centriolar satellite organization are not significantly modified in Cyld D932 mice.
Cyld D932 does not interact with CAP350. To gain molecular insight into the defects associated with CYLD D932 expression, we tested whether CYLD D932 protein interacted with CAP350 by immunoprecipitation of CAP350 in WT and Cyld D932 MEFs. In parallel experiments, CAP350 antibody immunoprecipitated CYLD (revealed by a polyclonal antibody directed against the amino-terminal domain) in WT but not Cyld D932 MEFs (Fig. 7) , suggesting that the truncated version of CYLD is unable to interact with CAP350. It follows that CYLD D932 would not be localized at the centrosome and, indeed, we did not detect any CYLD at the centrosome or basal bodies in Cyld D932 mutant ependymal cells (Fig. 7b,c) , while CAP350 remained at the centrosome. It is worth noting that CYLD was still localized at the ciliary tip in mutant ependymal cells. These observations indicate that the lack of interaction between CYLD D932 and CAP350 results in abnormal CYLD localization.
CYLD localization and activity are required for ciliogenesis.As the impaired ciliogenesis observed in Cyld D932 mice might be driven by the absence of CYLD at the centrosome, or by its compromised catalytic activity or both, we decided to investigate the effect of CYLD activity and localization on primary cilia formation. This was performed by overexpressing CYLD WT as well as its catalytically inactive version CYLD H871/N (ref. 24 ) in RPE1 cells. Overexpressed CYLD WT or CYLD H871/N protein is mainly cytosolic with no obvious enrichment at the centrosome (Fig. 8a) . We observed a dramatic decrease in primary cilia formation in cells expressing GFP-CYLD WT , CYLD WT -Flag or CYLD H871/N -Flag (Fig. 8a) with 23%, 17% and 24% of ciliated cells, respectively, while non-transfected cells or green fluorescent protein (GFP)-transfected cells showed B90%.
As this result could be due to aberrant CYLD localization, we decided to force CYLD expression at the centrosome using the centrosomal targeting domain, PACT 40 . The targeting of this GFP-PACT-CYLD WT to the centrioles affected ciliogenesis only ARTICLE slightly, resulting in B80% of ciliated cells (Fig. 8b) . By contrast, the targeting to the centrioles of CYLD with a point mutation, which impaired the catalytic activity of CYLD (GFP-PACT-CYLD H871/N ), showed only 57% of ciliated cells. A similar decrease was also observed (Fig. 8b, graph) when using the truncated and catalytically inactive version of CYLD, GFP-PACT-CYLD D932 (ref. 24) . To control that these observations are not caused by differences in the expression level of the constructs, we measured GFP fluorescence intensity at the centrosome for each condition in a new experiment. General observation of the slides showed similar differences in cell ciliation of transfected cells (ciliated cells: GFP-PACT-CYLD WT (82%), GFP-PACT-CYLD H871/N (60%), GFP-PACT-CYLD D932 (36%)), but no significant difference in mean fluorescence intensity was observed between ciliated and unciliated cells, irrespective of the construct, which shows that ciliation is independent of expression level (Fig. 8c ). These results demonstrate that both the localization of CYLD at the centrosome/basal body and its deubiquitinase activity are essential for its function in ciliogenesis.
Ciliogenesis defects are independent of NF-jB activation.A s CYLD is a negative regulator of the NF-kB signalling pathway, we were wondering whether the defective ciliogenesis observed on the trachea and ependymal cells of mutant mice or after targeting at the centrosome catalytically inactive CYLD, might be due to a deregulation of the NF-kB pathway. Therefore, we decided to cotransfect RPE1 cells with either GFP-PACT-CYLD WT or GFP-PACT-CYLD D932 with or without a non-degradable form of IkB acting a Super-repressor of NF-kB(IkBa Super-Repressor (IkBa-SR)) 41 to block NF-kB activation. As shown on Fig. 8d , the addition of the tumour necrosis factor (TNF) induced activation of NF-kB either in the presence of serum or after 48 h serum depletion, while the presence of IkBa-SR completely blocked this activation. In parallel, cells were fixed and analysed for the presence of a primary cilium. Expression of IkBa-SR did not impact the ciliation process either in GFP-PACT-CYLD WT -orin GFP-PACT-CYLD D932 -expressing cells as shown in Fig. 8e , suggesting that the defects in the ciliogenesis process due to the presence of GFP-PACT-CYLD D932 at the centrosome is independent of NF-kB signalling.
Discussion
In this study we demonstrate that part of the CYLD pool is located at the centrosome/basal bodies, through its interaction with CAP350. This interaction is attested by several observations.
First of all, we identified CYLD by mass spectrometry as a partner of CAP350 and confirmed their interaction in endogenous immunoprecipitation experiments; Furthermore, we demonstrate by co-overexpression that the C-terminal portion of CYLD, including the DUB domain, interacts with the C-terminal domain of CAP350. Second, CAP350 overexpression directs the centrosomal localization of overexpressed CYLD; finally, CYLD no longer localizes at the centrosome when its interaction with CAP350 is abolished. It is worth noting that CYLD has already been found in interaction with another centrosomal protein CEP192 in co-overexpressed conditions, reinforcing the centrosomal localisation of CYLD 16 . Nevertheless, the relationship ARTICLE between CAP350/CEP192 and CYLD will require further investigations. This specific centrosomal localization combined with the staining observed at the tip of motile cilia suggests that CYLD plays a role in cilia assembly/disassembly. Interestingly, localization of CYLD at the cilia tips is reminiscent of the enrichment observed for several other proteins such as EB1/EB3 (ref. 42) , some IFT proteins 43 and, more recently, cep104/FAP256 (ref. 44 ). This localization of CYLD is probably independent of its DUB activity, as the staining at the cilia tip is still observed in Cyld D932 ependymal cells. As a matter of fact, an interaction between CYLD and EB1 has recently been reported 45 . In any case, this dual CYLD localization at the centrosome and at the cilia tip suggests that CYLD has distinct functions depending on the partners it interacts with.
Our results show that CYLD participates in ciliogenesis by allowing basal bodies to migrate and dock to the plasma membrane. However, not all motile cilia are affected, as CYLD D932 mutants do not display any left-right patterning defects, suggesting that the function of the node is unaffected by CYLD truncation. In addition, we demonstrate that CYLD has to be both catalytically active and located at the centrosome to promote ciliogenesis. Therefore, we propose a model (Fig. 9 ) in which ciliogenesis would be only possible if a centrosomal protein, or CAP350 itself, is deubiquitinated. In the WT situation, CYLD would be located at the centrosome/basal body via CAP350 and be able to hydrolyse K63-or linear-linked ubiquitin chains from its substrate, enabling ciliogenesis to proceed. In the mutant situation, CYLD would not be present at the centrosome, resulting in impaired ciliogenesis. On CYLD overexpression, extra CYLD in the cytoplasm would delocalize its targets and prevent ciliogenesis. However, when CYLD is overexpressed and targeted to the basal body by the PACT domain, it can deubiquitinate its target and, consequently, ciliogenesis occurs. Conversely, cells overexpressing the catalytically inactive CYLD H871/N or CYLD D932 fused with the PACT domain do not retain the ability to develop cilia. All these results argue for the involvement of K63-ubiquitination/deubiquitination in ciliogenesis. Importantly, we demonstrate that this role is NF-kB independent. Recently, several reports have suggested an inhibition of ciliogenesis caused by activation of the NF-kB pathway. First, Lattke et al. 46 have shown that the activation of this pathway by the expression of constitutively active IKK2 inhibits cilia formation. However, it is not clear whether the cilia formation defect is a consequence of a direct cell-autonomous NF-kB activation rather than activation of inflammatory processes. Moreover, it could also be a direct effect of active IKK2 in ependymal cells, independently of NF-kB, as IKK2 has NF-kB-independent functions 47 . As a matter of fact, IKK2 has been found inhibiting ciliogenesis in an RNA interference screen 48 . Second, the pro-inflammatory cytokine TNF triggered a dose-dependent loss of primary cilia in mesenchymal stromal cells 49 , but no molecular explanation was provided. However, our study brings several arguments supporting the fact that this DUB acts on ciliogenesis independently of NF-kB activation as trachea from CYLD KO mice do not show any defects in motile cilia formation, whereas they are defective in NF-kB signalling 14, 18 , and inhibition of the NF-kB pathway by the expression of a nondegradable form of IkBa acting as a Super-repressor 41 do not modify the ciliogenesis defect caused by expression of the CYLD D932 protein at the centrosome.
Nevertheless, it is intriguing that Cyld KO mice are perfectly viable without any problem in motile cilia formation, whereas the mice expressing a truncated version of CYLD die at birth with cilia defects. These results suggest some redundancy in the control of ciliogenesis by DUBs. In the Cyld KO mice another DUB may compensate for the function of CYLD, whereas in the Cyld D932 mice the mutant CYLD protein probably acts as a dominant negative by delocalizing its substrate, thus preventing the action of the substitute DUB. USP 21 is a good candidate for carrying this function, as it has recently been shown to localize at the centrosome and affect primary cilia formation 50 . Moreover, it shares a similar target with CYLD in the regulation NF-kB signalling pathway 51 .
The involvement of the deubiquitinase CYLD in basal body migration/docking has to be integrated in a more general role of ubiquitination processes in ciliogenesis or centrosomal function. At first, ubiquitinated proteins have been reported to be present in cilia and flagella 52 , and the K63-specific E2 ubiquitinconjugating enzyme Ubc13 is present in the ciliome of various species [52] [53] [54] [55] . Next, protein ubiquitination was involved in flagellar disassembly 52 . Finally, the E3 ubiquitin ligase MIB1 (ref. 56 ) was identified in a centrosome proteome 57 and the deubiquitinase USP21 is shown to be required for primary cilia formation 50 .I n addition, another deubiquitinase Usp33 has recently been shown to localize at the centrosome by its binding with CP110 and its activity antagonizes SCF cyclinF ubiquitination of CP110 (ref. 58) .
How may CYLD regulate ciliogenesis? Our data show that CYLD is required to allow basal body migration and docking at the plasma membrane. We also show that centriole maturation It is worth noting that after w 2 -test statistically significant differences can be observed irrespective of the PACT-CYLD fusion construct after NF-kB inhibition.
proteins as well as some centriolar satellite proteins are still present in our mutants, suggesting that the anchoring defect is not a result of basal body structural defects. However, we cannot rule out that ubiquitination/deubiquitination processes might affect centriole appendages and centriolar satellite functions 59, 60 .
Interestingly, a target of CYLD, Dvl 15 , has been shown in Xenopus multiciliated cells to be essential for the positioning of the apical basal bodies and for the activation of the Rho GTPase 61 . In addition, the RhoGEF LARG, co-immunoprecipitates with CYLD 62 . Therefore, we propose that CYLD would allow basal body migration by deubiquitinating, a substrate working with Dvl, and LARG to activate RhoA GTPase and subsequently remodel actin. The recent report that phosphorylated CYLD redistributes to the dorsal ruffles 63 supports this hypothesis of a link between CYLD and the actin network.
In conclusion, our work identifies CYLD as a new regulator of ciliogenesis. Two recent studies 64, 65 have recently reported that impaired ciliogenesis impacts skin homeostasis and affects the pilosebaceous unit from which cylindroma are believed to originate. This convinced us that future studies designed to precisely characterize the molecular pathways regulated by CYLD during ciliogenesis might provide novel insights into how CYLD deregulation results in cylindroma in the cylindromatosis pathology.
Methods
Mice. All animals were housed in specific pathogen-free conditions at Institut Curie according to French and European Union laws. All animal procedures were conducted in accordance with European, national and institutional guidelines and protocols, and were approved by local government authorities (Authorization for animal testing N°91-518, Direction départementale des services vétérinaires de l'Essonne).
Cyld D932 and Cyld KO mice were generated in a c57/Bl6J background as described previously 23, 30 . Male and female embryos were used. As no differences between Cyld D932 heterozygous mice or embryos and their WT littermates were observed throughout the study, we pooled the results of both genotypes under the classification of WT. The embryonic stage was estimated on the basis of gestational time, with day 0.5 being defined as the morning when a vaginal plug was detected. Adult mice and embryos were genotyped by PCR.
Cell culture. Human retinal pigment epithelial (RPE1) cells were obtained from ATCC and grown in DMEM/F12 medium supplemented with 10% FCS. Human lymphoblastic KE37 cells obtained from M. Bornens's laboratory were grown in RPMI medium supplemented with 10% FCS. MEFs were obtained after trypsinization of dissected embryos at embryonic day 13.5 (E13.5) and grown in DMEM medium supplemented with 10% FCS and non-essential amino acids. Ependymal cell cultures were maintained as described previously 21, 66 . Human embryonic kidney cells (HEK293T) from ThermoScientific were transiently transfected with plasmid DNA using the calcium phosphate precipitation method. RPE1 cells were transiently transfected with plasmid DNA using X-tremeGENE HP (Roche) or Nucleofection (Amaxa) and fixed 24-48 h after transfection.
Cellular fractionation. Centrosomes were isolated from KE37 cells as described previously 67 . Briefly, cells were pretreated for 1 h with Nocodazole (2 Â 10 À 7 M) and Cytochalasin D (1 mgml À 1 ). Cells were washed in PBS and resuspended in 8% sucrose in ten times diluted PBS before cell lysis in lysis buffer (1 mM HEPES, 0.5 mM MgCl 2 , 0.5%NP40, 1 mM phenylmethanesulphonyl fluoride and antiproteases). After centrifugation at 2,500 g, the supernatant is filtered through a nylon-mesh and readjusted to 10 mM HEPES and treated with DNAse. Concentrated centrosomes were overlaid on a discontinuous sucrose gradient (70%, 50% and 40%) in a SW28 tube and centrifuged for 1 h 15 min at 26,000 r.p.m. Fractions were collected and analysed for centrosomes. ARTICLE One percent Triton X-100 soluble or insoluble cell fractions were isolated from KE37 or RPE1 cells as described by Tassin et al. 68 Plasmid construction. Full-length CAP350 and CYLD cDNAs were subcloned into a GFP vector (GFP-C3 from Clontech) for expression of GFP-tagged proteins. Different fragments of CAP350 cDNAmyc-tagged corresponding to AA 1-893, 984-2589 and 2590-3117 were previously described 8 . The CYLD-Flag construct was previously described 24 .TheDC CYLD construct was designed by introducing a stop codon in AA 586.
The PACT domain was amplified from human AKAP450 and then subcloned into the GFP-CYLD vectors. All constructions have been verified by sequencing.
Antibodies. Three antibodies directed against CYLD were used: a polyclonal antibody obtained by immunizing rabbits against the N-terminal region (amino acids 1-555) of CYLD (CYLD 089) and affinity purified (diluted 1/1,000 for WB analysis and 1/300 for immunofluorescence (IF), a monoclonal antibody directed against the full-length CYLD supplied by Millipore, which does not recognize endogenous protein from RPE1 and HEK293T cells (diluted 1/500 for WB analysis) and a monoclonal antibody supplied by Santa Cruz Biotechnology (E-10, SC-74435) recognizing the catalytic domain of the protein (diluted 1/100 for WB analysis). All antibodies have been characterized by the following procedure: they are recognized by WB analysis and IF overexpressed GFP-CYLD, as well as the immunoprecipitated protein. However, the polyclonal one gave a stronger signal both in IF and WB analysis. Two antibodies directed against g-tubulin were used: a previously described polyclonal antibody 68 (1/500) and a monoclonal one (GTU88 from Sigma 1/ 1,000). We also used affinity-purified rabbit polyclonal antibodies directed against Centrin 3 (ref. 36 (1/100), ODF2 (residus 250-632) 48 (1/1,000) and several anti-tubulin antibodies were used, such as detyrosinated tubulin (T12)(1/1,000), polyglutamylated-tubulin (GT335) (1/50,000) and monoglycylated tubulin (TAP) (1/50,000) as described in Janke and Bulinski 22 . Antibodies against acetylated tubulin (clone 6-11 B 1) (1/ 1,000) and tubulin (clone B5-1-2) were purchased from Sigma and rabbit anti-Ki67 (1/500) (Novocastra Laboratories). DAPI (4 0 ,6-diamidino-2-phenylindole, Sigma) was used for DNA labelling. In all experiments using Flag antibodies, we used the anti-flag M2 from Sigma (F1804)(1/1,000). Only the WB analysis of the DN CYLD was revealed by Rabbit anti-Flag antibodies (F7425) (1/500).
Western blotting. Protein extracts were run on a PAGE gel of various acrylamide/ bisacrilamyde percentages. Gels were transferred on nitrocellulose membranes with a semi-dry transfer device (Bio-Rad). Membranes were then blotted with various antibodies then revealed by electrochemiluminescence on autoradiographs. Noncropped scans of the autoradiograps of the main WB analysis are presented in Supplementary Fig. 6 . IF microscopy and data processing. Cells were either fixed with methanol for 6 min at À 20°C and permeabilized for 30 s in PHEM buffer containing 0.25% Triton X-100 before methanol fixation or fixed with 4% paraformaldehyde for 15 min before permeabilization with 1% Triton X-100 and processed for IF as described previously 68 .
After immunostaining, three-dimensional microscopy was performed using an upright motorized microscope (DM RXA2, Leica Microsystems, Mannheim, Germany) equipped with an oil immersion Â 40, Â 63, Â 100/numerical aperture 1.4 Plan-Apochromat objective lens and a cooled interline charge-coupled device detector (Photometrics Coolsnap HQ). Z-positioning was accomplished using a piezoelectric driver (LVPZT, Physik Instruments, Waldbronn, Germany) mounted underneath the objective lens. The whole system operated using Metamorph software (Universal Imaging Corp., Downingtown, PA). Z-stacks were generated from optical sections taken at 0.2-mm intervals. Z-stacks were deconvoluted using Metamorph software with the appropriate point spread function (PSF) and Meinel algorithm.
In Fig. 8c , pictures were taken with a wide-field fluorescence microscope (Zeiss Axiovert 200 M equipped with an Hamammatsu C4742 camera). For each picture in the GFP channel, all parameters were kept identical (exposure time, binning, camera gain, Offset and so on). Average pixel fluorescence intensity of GFP at the centrosome was then measured within a defined and constant circular area of the size of a centriole, using the measurement tools of Image J. Quantification data were compiled from measurements of 80 cells from each of the 3 constructs. Raw measurements for each 80 cells are plotted along the y axis in the graph to make comparison easier.
Immunoprecipitation experiments. Proteins from RPE1, HEK293T or MEF cells were extracted with 1D buffer 15, 68 . After a centrifugation to eliminate trace aggregates, primary antibodies preadsorbed to protein G-sepharose beads (Pharmacia) were added to the sample and the mixture incubated for 2 h at 4°C. Protein G-sepharose beads were then sedimented. The sedimented protein G-sepharose beads were washed (five times) with buffer and supernatants were precipitated with cold methanol. Proteins were then processed for SDS-PAGE electrophoresis and WB analysis.
For mass spectrometry analysis, the protein spots were excised from the gel after coloration with colloidal Coomassie blue (G250; Bio-Rad), reduced using dithiothreitol and alkylated using iodoacetamide. The proteins were subjected to digestion with trypsin (Sigma). The extracted peptides were analysed by matrixassisted laser desorption-ionization-time of flight mass spectrometry (Voyager-DETM PRO, Applied Biosystems). Peptide masses obtained by this analysis were used to search the National Center for Biotechnology Information database to identify the full-length proteins.
Scanning electron microscopy. Tracheas were dissected from embryos at embryonic day 18.5 (E18.5), fixed overnight in 2.5% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer pH 7.2 and post-fixed with 2% osmium tetroxide (Electron Microscopy Sciences). Samples were dehydrated in a graded ethanol series and dried with hexamethyldisilazane (HMDS) or the CO 2 critical point dryer Leica CPD-030. Specimens were coated with 10 nm gold/palladium in a Gatan Ion Beam Coater 681 and observed in a field emission scanning electron microscope JSM-6700f (JEOL, Japan). Image processing and analyses were performed with ImageJ software.
Transmission electron microscopy. Tracheas were dissected from embryos at E18.5, fixed overnight in 2.5% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer pH 7.2 and post-fixed with 2% osmium tetroxide. Samples were dehydrated in a graded ethanol series and embedded in Epon (Electron Microscopy Science). Longitudinal 200-nm-thick sections were prepared with an ultramicrotome (Leica) and mounted on copper grids (200 mesh). The samples were observed in a 200-kV field emission gun electron microscope with an in-column energy filter (omega filter) JEM 2200 FS (JEOL, Japan).
Cilia counting and statistics. As ciliated cells in the trachea differentiate proximo-distally, we counted the cells in a series of jointed pictures taken from the larynx to the main bronchi to avoid any bias based on differentiation time. For a better visualization, results were normalized. This was achieved by taking the number of ciliated cells of WT embryos as 100%. In MEF cell cultures, primary cilia formation is not always homogeneous. Therefore, we took the pictures for counting in a randomized manner, observing the centrosome. The same field was then examined for the presence of cilia.
Most of the experiments needing statistical validation involved paired observations on two variables for which we wanted to assess the independence of two populations. In those cases, the events being considered were mutually exclusive and the total probability was one. All observations were independent. Therefore, we used Fisher's exact test or, when the sample sizes were large enough to avoid a type II error following Cochran's rules, we performed Pearson's w 2 -test without Yates' correction. All calculations were made with GraphPad Prism 5. Statistical significance in the fluorescence intensity experiment (Fig. 8) was assessed via a Mann-Whitney test. The P-value is ranked based on the exact value given by the software. All error bars show s.d.
In one experiment, it was not possible to run any statistical test because of the nature of the data. To count ciliated cells in the tracheas of embryos, we had to compare individuals within the same litter to avoid bias arising from possible developmental differences between two litters. Consequently, there were too few embryos in each litter to perform statistical testing.
FACS analysis. Cell cycle profiles of cycling as well as serum-starved WT or Cyld D932 MEFs were determined by analysing total DNA content using propidium iodide staining (1 h incubation of ethanol-fixed cells in PBS containing 20 mgml À 1 propidium iodide, 100 mgml À 1 RNase A, and 0.1% Triton X-100). Cells were subjected to flow cytometry by using a FACSCalibur analyser (BD Biosciences) and the results were analysed with FlowJo.
NF-jB inhibition by IjBa-SR. RPE1 cells were transfected by GFP-PACT-CYLD WT , GFP-PACT-CYLD H/N or GFP-PACT-CYLD D932 plasmids in the presence of an Ig-kB-Luc reporter plasmid with or without a plasmid expressing a non-degradable form of IkBa (IkBa-SR) 41 . Cells were serum starved 24 h after transfection to induce cilia formation and fixed 48 h after serum depletion for cilia analysis. To measure the effect of IkBa-SR, cells were stimulated with 10 ng ml À 1 of TNF-a just before removing the serum (24 h after transfection) or 3 h before completing the experiment. Cell extracts were prepared and Ig-kB-Luciferasederived activity measured using a LB 9507 Berthold Luminometer.
